Literature DB >> 2156205

Antiviral xanthate causes conformational changes in simian virus 40 DNA and chromatin.

W Waldeck1.   

Abstract

Xanthates possess a wide antiviral and antitumoral spectrum. Treatment of simian virus 40 (SV40)-infected cells with tricyclo-decan-9-yl-xanthate (D609) reduces transcription and replication. Concomitantly, we observed condensation of the SV40 minichromosomes after addition of D609 to the tissue culture. The structural change of the viral chromatin was measured as an increase in sedimentation behavior from 95-75 to 180-150 Svedberg units. A modulation of the DNA structure was detected in parallel, resulting in an increase in the topological linking number of the SV40 DNA by two superhelical turns above the average superhelicity in the infected cell. Therefore, enzyme activities responsible for topological changes (topoisomerases) were examined and an inhibition of topoisomerase I by more than 1,000-fold was detected.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156205     DOI: 10.1159/000226815

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.

Authors:  Laura Fantuzzi; Francesca Spadaro; Cristina Purificato; Serena Cecchetti; Franca Podo; Filippo Belardelli; Sandra Gessani; Carlo Ramoni
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

Review 2.  Ceramide and Related Molecules in Viral Infections.

Authors:  Nadine Beckmann; Katrin Anne Becker
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 3.  Tricyclodecan-9-yl-Xanthogenate (D609): Mechanism of Action and Pharmacological Applications.

Authors:  Aashiq Hussain Bhat; Khalid Bashir Dar; Andleeb Khan; Saeed Alshahrani; Sultan M Alshehri; Mohammed M Ghoneim; Prawez Alam; Faiyaz Shakeel
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.